0808 GMT - DSM-Firmenich will likely communicate on capital returns in advance of further divestment, Jefferies analysts write in a note. The sale of its stake in the Feed Enzymes Alliance to its partner Novonesis brings focus to its balance sheet, the analysts say. "The combination of this divestment and the previously announced Robertet sale represents around 1.8 billion euros of net proceeds from divestment," they add. This suggests that the Dutch nutrition, health and bioscience company could communicate on capital returns even before the finalized remaining Animal Nutrition and Health sale. Shares closed Monday at 95.94 euros. (najat.kantouar@wsj.com)
(END) Dow Jones Newswires
February 11, 2025 03:08 ET (08:08 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.